Compare SND & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SND | GLSI |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | 318 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.0M | 254.7M |
| IPO Year | 2016 | 2020 |
| Metric | SND | GLSI |
|---|---|---|
| Price | $5.07 | $15.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | ★ 210.6K | 117.9K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $330,153,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.80 | ★ N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $2.05 | $7.78 |
| 52 Week High | $5.92 | $34.10 |
| Indicator | SND | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 42.79 |
| Support Level | $4.99 | $14.57 |
| Resistance Level | $5.11 | $19.97 |
| Average True Range (ATR) | 0.18 | 1.44 |
| MACD | -0.03 | -0.26 |
| Stochastic Oscillator | 19.61 | 19.33 |
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.